Écrit par Pluristem | 07 Août 2012

Clinical trial to demonstrate safety and efficacy of PLX cells for regeneration of injured gluteal muscle following total hip replacement

HAIFA, ISRAEL, August 7, 2012 -- Pluristem Therapeutics, Inc. (NASDAQCM:PSTI; TASE: PLTR), a leading developer of placenta-based cell therapies, today announced it has received approval from the Paul-Ehrlich-Institute (PEI), the medical regulatory body...

Écrit par Enbo Journal | 06 Août 2012

HEIDELBERG, 6 August 2012 – Intellectual disability due to Fragile X and Down syndromes involves similar molecular pathways report researchers in The EMBO Journal. The two disorders share disturbances in the molecular events that regulate the way nerve cells develop dendritic spines, the small extensions found on the surface of nerve cells that are crucial for communication in the...

Écrit par GlobalData | 01 Août 2012

LONDON, UK (GlobalData), 26 July 2012 - IntelligentMDx received EU approval of their new diagnostic test, IMDx HSV-1/2, which detects the presence of HSV nucleic acids and differentiates between Herpes simplex virus 1 and 2 (HSV-1 and HSV-2). The IMDx HSV-1/2 is designed to complement the use of the Abbott m2000 RealTime system, manufactured by Abbott Molecular, a subsidiary of Abbott...

Écrit par Pluristem | 23 Juillet 2012

HAIFA, ISRAEL, July 18, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR), today announced that in anticipation of initiating a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company has recently entered into a collaborative agreement with CPC Clinical Research (CPC) for services related to enrolling and sustaining clinical sites...